ArticleInternational journal of general medicine2026
The Role of COQ10B in Tumor Progression and Its Association with Immune Escape in Esophageal Squamous Cell Carcinoma: A Multi-Omics and Functional Analysis.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to investigate the role of coenzyme Q10B (COQ10B) in esophageal squamous cell carcinoma (ESCC) and elucidate its potential mechanisms in regulating the tumor immune microenvironment. Patients and Methods: This study integrates bioinformatics, in vitro cell experiments, and in vivo animal models. First, the TCGA and GEO databases were used to analyze correlations between COQ10B expression and ESCC prognosis, signaling pathways, and immune cell infiltration, and single-cell sequencing data were combined to establish its cellular expression profile. Second, TE-1 cells were lentivirally transfected to overexpress COQ10B, and colony formation, EdU, scratch, and Transwell assays were conducted to assess the effects on proliferation, migration, and invasion. Finally, a subcutaneous xenograft model in C57BL/6 mice evaluated COQ10B overexpression and PI3K inhibitor (LY294002) effects on tumor growth, PD-L1 expression, PI3K/AKT/HIF-1A pathway, and immune cell (CD4+ T cells, M2 macrophages) infiltration via Western blotting and flow cytometry. Results: Bioinformatics showed that COQ10B was highly expressed in ESCC and was significantly associated with poor prognosis. Its expression positively correlated with the PI3K-AKT and HIF1 pathways, cancer stem cell genes, and macrophage infiltration. In vitro, COQ10B overexpression enhanced ESCC cell proliferation, migration, and invasion. In vivo, it promoted tumor growth, upregulated PD-L1, p-PI3K, p-AKT, and HIF-1A, reduced CD4+ T cells, and increased M2 macrophages. The PI3K inhibitor LY294002 reversed these pro-tumor and immunosuppressive effects. Conclusion: High COQ10B expression is closely associated with ESCC progression and poor prognosis. These malignant biological behaviors and the associated immunosuppressive tumor microenvironment are potentially mediated via the activation of the PI3K/AKT/HIF-1A signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.